Biomedical research is largely centered on making new discoveries as it relates to human health and disease. The ultimate goal is to understand how human biology works and when and why it goes awry. With a strong foundation on the mechanisms of health and disease, advances in diagnostics and therapeutic interventions can be generated bringing cures to recalcitrant diseases such as cancer and neurodegenerative pathologies.
As part of our focus, we present this podcast where we talk to Mark Savage who discusses how software tools can address certain challenges and bring forward compounds from discovery to development.
From fundamental ion chemistry to differential mobility spectrometry: An interview with Larry Campbell from SCIEX
In this expert interview, we talk to Larry Campbell (SCIEX) about ion mobility technology focusing on SelexIONTM differential mobility spectrometry technology.
This chapter discusses important considerations when transferring various types of chromatographic-based assays in today’s pharmaceutical research and development environment.
New analytical method enables researchers to identify and quantify lipids isomers, potentially allowing for early diagnosis of cancer.
In this research article a HPLC method for determination and enantiomeric resolution of dl-carnitine in human plasma is presented.
A new study concludes that approximately six to nine fingerprick blood drops are required to obtain consistent results. Healthcare professionals should be aware of this variation in real life scenarios.
Researchers develop optical attachment and smartphone app that allows quantitative analysis of paper-based saliva alcohol tests.
Simple, inexpensive sorbent tube for the sampling of volatile organic compounds developed by Florida International University researchers.
A Raman spectroscopy based diagnostic system for the analysis of kidney stones is being developed by researchers at the Fraunhofer Institute for Physical Measurement Techniques IPM, in collaboration with the University Medical Center Freiburg and an industrial partner.